Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
J Pediatr Ophthalmol Strabismus ; 44(5): 315-7, 2007.
Article in English | MEDLINE | ID: mdl-17913179

ABSTRACT

Three cases of severe globe injuries due to scleral fragility in osteogenesis imperfecta patients between the ages of 4 and 15 years are reported. Patient 1 had complete loss of vision. Patients 2 and 3 suffered non-sight-threatening scleral perforation. All 3 patients had no previous knowledge of recommendation for eyewear protection.


Subject(s)
Eye Injuries/etiology , Osteogenesis Imperfecta/complications , Sclera/injuries , Scleral Diseases/etiology , Uveal Diseases/etiology , Adolescent , Child , Child, Preschool , Eye Injuries/diagnosis , Eye Injuries/surgery , Female , Humans , Male , Osteogenesis Imperfecta/diagnosis , Prolapse , Rupture , Rupture, Spontaneous , Scleral Diseases/diagnosis , Scleral Diseases/surgery , Uveal Diseases/diagnosis , Uveal Diseases/surgery
3.
Hum Mutat ; 23(3): 222-8, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14974080

ABSTRACT

We have previously reported that loss-of-function mutations in the cathepsin C gene (CTSC) result in Papillon-Lefèvre syndrome, an autosomal recessive condition characterized by palmoplantar keratosis and early-onset, severe periodontitis. Others have also reported CTSC mutations in patients with severe prepubertal periodontitis, but without any skin manifestations. The possible role of CTSC variants in more common types of non-mendelian, early-onset, severe periodontitis ("aggressive periodontitis") has not been investigated. In this study, we have investigated the role of CTSC in all three conditions. We demonstrate that PLS is genetically homogeneous and the mutation spectrum that includes three novel mutations (c.386T>A/p.V129E, c.935A>G/p.Q312R, and c.1235A>G/p.Y412C) in 21 PLS families (including eight from our previous study) provides an insight into structure-function relationships of CTSC. Our data also suggest that a complete loss-of-function appears to be necessary for the manifestation of the phenotype, making it unlikely that weak CTSC mutations are a cause of aggressive periodontitis. This was confirmed by analyses of the CTSC activity in 30 subjects with aggressive periodontitis and age-sex matched controls, which demonstrated that there was no significant difference between these two groups (1,728.7 +/- SD 576.8 micro moles/mg/min vs. 1,678.7 +/- SD 527.2 micro moles/mg/min, respectively, p = 0.73). CTSC mutations were detected in only one of two families with prepubertal periodontitis; these did not form a separate functional class with respect to those observed in classical PLS. The affected individuals in the other prepubertal periodontitis family not only lacked CTSC mutations, but in addition did not share the haplotypes at the CTSC locus. These data suggest that prepubertal periodontitis is a genetically heterogeneous disease that, in some families, just represents a partially penetrant PLS.


Subject(s)
Aggressive Periodontitis/genetics , Cathepsin C/physiology , Papillon-Lefevre Disease/genetics , Periodontitis/genetics , Adult , Cathepsin C/genetics , DNA Mutational Analysis/methods , Female , Genetic Markers/genetics , Genotype , Haplotypes/genetics , Humans , Male , Models, Molecular , Mutation, Missense/genetics , Pedigree , Point Mutation/genetics , Polymorphism, Genetic/genetics , Protein Structure, Tertiary/genetics
4.
Mol Ther ; 5(6): 685-94, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12027552

ABSTRACT

A major focus in the basic science of gene therapy is the study of factors involved in target-specific regulation of gene expression. Optimization of artificial or "designer" transcription factors capable of specific regulation of target genes is a prerequisite to developing practical applications in human subjects. In this paper, we present a systematic and combinatorial approach to optimize engineered transcription factors using designed zinc-finger proteins fused to transcriptional effector domains derived from the naturally occurring activators (VP16 or P65) or repressor (KRAB) proteins. We also demonstrate effective targeting of artificial transcription factors to regulate gene expression from three different constitutive viral promoters (SV40, CMV, RSV). Achieving a desired level of gene expression from a targeted region depended on several variables, including target site affinities for various DNA-binding domains, the nature of the activator domain, the particular cell type used, and the position of the target site with respect to the core promoter. Hence, several aspects of the artificial transcription factors should be simultaneously evaluated to ensure the optimum level of gene expression from a given target site in a given cell type. Our observations and our optimization approach have substantial implications for designing safe and effective artificial transcription factors for cell-based and therapeutic uses.


Subject(s)
Gene Expression Regulation , Protein Engineering , Transcription Factors/genetics , Zinc Fingers/genetics , Cytomegalovirus/genetics , Genetic Vectors , Kinetics , Promoter Regions, Genetic , Protein Structure, Tertiary , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Simian virus 40/genetics , Transcription Factors/metabolism
5.
Am J Med Genet ; 108(1): 57-63, 2002 Feb 15.
Article in English | MEDLINE | ID: mdl-11857551

ABSTRACT

Cystathionine beta-synthase (CBS) deficiency, the most common form of homocystinuria, is an autosomal recessive inborn error of homocysteine metabolism. Treatment of B6-nonresponsive patients centers on lowering homocysteine and its disulfide derivatives (tHcy) by adherence to a methionine-restricted diet. However, lifelong dietary control is difficult. Betaine supplementation is used extensively in CBS-deficient patients to lower plasma tHcy. With betaine therapy, methionine levels increase over baseline, but usually remain below 1,500 micromol/L, and these levels have not been associated with adverse affects. We report a child with B6-nonresponsive CBS deficiency and dietary noncompliance whose methionine levels reached 3,000 micromol/L on betaine, and who subsequently developed massive cerebral edema without evidence of thrombosis. We investigated the etiology by determining methionine and betaine metabolites in our patient, and several possible mechanisms for her unusual response to betaine are discussed. We conclude that the cerebral edema was most likely precipitated by the betaine therapy, although the exact mechanism is uncertain. This case cautions physicians to monitor methionine levels in CBS-deficient patients on betaine and to consider betaine as an adjunct, not an alternative, to dietary control.


Subject(s)
Betaine/adverse effects , Brain Edema/etiology , Homocystinuria/complications , Methionine/blood , Betaine/metabolism , Brain Edema/blood , Brain Edema/chemically induced , Child , Child, Preschool , Female , Homocystinuria/diet therapy , Humans , Infant , Infant, Newborn , Treatment Refusal
SELECTION OF CITATIONS
SEARCH DETAIL
...